This study is testing a new treatment called MDX2301 in healthy adults and adults who are at higher risk for severe COVID-19. Researchers want to see how safe MDX2301 is, how well your body tolerates it, and how it moves through your system. You would receive MDX2301 or a placebo (like normal saline, which has no active medicine) through an IV (intravenous infusion, into a vein), IM (intramuscular injection, into a muscle), or SC (subcutaneous injection, under the skin). Some participants will receive a single dose, and others will receive a second dose about three months later. The study will track any side effects for up to approximately 12 months.

Study design

This interventional study plans to enroll 80 participants. It is a first-in-human study, meaning it's the first time MDX2301 is being tested in people.

What's involved

Participants will receive single doses of MDX2301 or placebo, and some will receive a repeat dose approximately 3 months later. The study will monitor you for up to approximately 12 months.

Compensation

Not stated in the trial record.

Follow-up

You will be followed for adverse events (side effects) from the start of the study until its end, which is up to approximately 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.